Deciphera Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 3, 2021
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its second quarter 2021 financial results on Tuesday, August 3, 2021.
In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, August 3, 2021, to discuss the Company’s financial results and provide a corporate update.
The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 9943767. A webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumors. For more information, visit https://www.deciphera.com/ or follow us on LinkedIn and Twitter (@Deciphera).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005370/en/
Deciphera Pharmaceuticals Stock
Deciphera Pharmaceuticals is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a current price of 23.8 € Deciphera Pharmaceuticals is right around the predicted target price of 24 €.